Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course cyclophosphamide followed by mycophenolate mofetil versus long-course cyclophosphamide for proliferative lupus nephritis
NL-OMON29290Active, not recruiting
- Sponsor
- Nierstichting
- Start
- Jan 2003
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cyclophosphamide, mycophenolate mofetil, prednisone and azathioprine in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Nierstichting. Primary endpoint: Number of renal relapses. Started Jan 2003; status: active, not recruiting.
02
Drugs
cyclophosphamidemycophenolate mofetilprednisoneazathioprine
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON29290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29290.